Insilico Medicine's INS018_055 Nominated for Breakthrough Therapy Designation; Xingqi Pharma Reports 320% YoY Net Profit Surge in Q1
Xingqi Pharmaceutical
Ophthalmic Drug Research, Development, Production, and Sales
Tigermed
Biopharmaceutical R&D Service Provider
WuXi AppTec
New Drug R&D and Production Service Provider
PegBio
Developer of Innovative Therapies for Chronic Diseases
Medtronic
Medical Device Manufacturer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
AI Drug Development Gains Further Recognition.
On April 28, according to the CDE official website, Insilico Medicine's INS018_055 tablet is proposed to receive Breakthrough Therapy Designation for the treatment of idiopathic pulmonary fibrosis.
The medical industry's first quarter reports are being released intensively.
On April 28, Xingqi Pharmaceutical announced that its first quarter report for 2025 recorded operating revenue of 536 million yuan, an increase of 53.24% year-on-year; the net profit attributable to shareholders of the listed company was 146 million yuan, an increase of 319.86% year-on-year.
On the same day, Tigermed announced that its revenue for the first quarter of 2025 was RMB 1.564 billion, a year-on-year decrease of 5.79%; net profit was RMB 165 million, a year-on-year decrease of 29.61%.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Capital Information
1) WuXi AppTec's Q1 Net Profit Increased by 89.06% Year-on-Year
On April 28, WuXi AppTec announced that it achieved operating revenue of 9.655 billion yuan in the first quarter of 2025, representing a year-on-year increase of 20.96%; net profit attributable to shareholders of the listed company was 3.672 billion yuan, representing a year-on-year increase of 89.06%.
2) Xingqi Pharmaceutical's Q1 net profit increased by 320% year-on-year
On April 28, Xingqi Pharmaceutical announced that its first quarter report for 2025 recorded operating revenue of 536 million yuan, representing a year-on-year increase of 53.24%; net profit attributable to shareholders of the listed company was 146 million yuan, marking a year-on-year increase of 319.86%.
3) Tigermed's Q1 net profit decreased by 29.61% year-on-year
On April 28, Tigermed announced that its revenue in the first quarter of 2025 was RMB 1.564 billion, a year-on-year decrease of 5.79%; net profit was RMB 165 million, a year-on-year decrease of 29.61%.
4) PegBio Passes Hearing and is About to List in Hong Kong
Recently, according to the website of the Hong Kong Stock Exchange, PegBio has passed the listing hearing and is about to be listed on the Hong Kong stock market.
/ 02 /
Pharmaceutical News
1) Insilico Medicine's INS018_055 Tablets to Receive Breakthrough Therapy Designation
On April 28, according to the CDE official website, Insilico Medicine's INS018_055 tablet is proposed to receive Breakthrough Therapy Designation for the treatment of idiopathic pulmonary fibrosis.
2) Xueji Bio's Platelet Injection New Drug Granted FDA Orphan Drug Designation
Recently, Xueji Biotech announced that its newly developed platelet injection cell drug XJ-PLT-001 has been granted Orphan Drug Designation by the U.S. FDA for the treatment of Bernard-Soulier Syndrome.
/ 03 /
Instrument Tracking
1) Medtronic Drug-Eluting Coronary Stent System Receives Registration Approval
On April 28, according to the NMPA website, Medtronic's drug-eluting coronary stent system received registration approval.
/ 04 /
Overseas Pharmaceutical News
1) Merck KGaA to Acquire SpringWorks for $3.9 Billion
On April 28, Merck KGaA of Germany announced that it would acquire SpringWorks for an equity value of approximately US$3.9 billion, or an enterprise value of US$3.4 billion based on SpringWorks' cash balance as of December 31, 2024.
PS: Welcome to scan the QR code below to add the WeChat ID of Amino for communication.